Last Updated: November 16, 2026

Details for Patent: 10,952,990

« Back to Dashboard


Which drugs does patent 10,952,990 protect, and when does it expire?

Patent 10,952,990 protects SOFDRA and is included in one NDA.

This patent has ninety-seven patent family members in twenty-two countries.

Summary for Patent: 10,952,990
Title:Formulation for soft anticholinergic analogs
Abstract:Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
Inventor(s):Nicholas S. Bodor, John J. Koleng, David Angulo
Assignee: Bodor Laboratories Inc
Application Number:US16/704,736
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

United States Patent 10,952,990: Sofpironium Bromide Hyperhidrosis Claims, Patent Scope, and Exclusivity Landscape

U.S. Patent No. 10,952,990 protects a method of treating hyperhidrosis with an anhydrous, ethanol-based topical gel containing a defined quaternary ammonium anticholinergic, hydroxypropyl cellulose, isopropyl myristate, citric acid, and hexylene glycol. The patent is directed to the formulation and its clinical use, rather than to every topical sofpironium product.

The commercial product most closely associated with the claim set is Sofdra, a 12.45% sofpironium topical gel developed and marketed by Brickell Biotech for primary axillary hyperhidrosis. The FDA approved Sofdra on June 18, 2024. [1]

What drug and formulation does U.S. Patent 10,952,990 protect?

The patent covers a topical formulation containing a sofpironium-related compound, particularly the stereoisomer identified in dependent claims 8 through 12:

(2R,3'R)-3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

This compound is commonly identified as sofpironium bromide. Sofpironium is a locally administered anticholinergic designed to reduce eccrine sweat production by inhibiting muscarinic signaling in sweat glands.

The independent claim requires all of the following:

Claim element Required limitation
Indication Treatment of hyperhidrosis
Route Topical administration to affected skin
Timing Administration before bedtime
Efficacy At least 25% reduction in sweat production for at least six hours
Comparator Performance substantially equivalent to the same concentration of glycopyrrolate
Safety Improved safety profile compared with topical glycopyrrolate
Dosage form Anhydrous topical gel
Active ingredient Formula (2) compound with specified stereochemical configuration
Solvent Anhydrous ethanol
Rheology agent Hydroxypropyl cellulose
Lipophilic excipient Isopropyl myristate
Other excipients Citric acid and hexylene glycol
Stability Greater storage stability than an aqueous solvent or aqueous-buffer formulation
Concentration About 1% to about 25% active compound

A competing product must satisfy every material limitation of claim 1 to create a strong literal-infringement case. A formulation that contains sofpironium but uses water, omits hydroxypropyl cellulose, lacks isopropyl myristate, or does not meet the claimed clinical performance limitations may fall outside the literal scope of the independent claim.

How broad is claim 1 of U.S. Patent 10,952,990?

Claim 1 is commercially important but structurally narrow. It combines composition, use, dosing-time, comparative clinical-performance, safety, and stability limitations in a single method claim.

The claim is broad in several respects:

  1. It covers a concentration range from approximately 1% to 25%.
  2. It covers more than one stereochemical configuration at the 1' and 3' positions.
  3. It allows optional additional carriers or excipients.
  4. It does not limit treatment to a particular body site, such as the axilla.
  5. It does not require a specific commercial container.
  6. It covers a range of sweat-reduction performance rather than a single absolute endpoint.

The claim is narrow in other respects:

  1. The formulation must be anhydrous.
  2. Ethanol must be anhydrous.
  3. Hydroxypropyl cellulose must be the gelling or viscosity-controlling ingredient.
  4. Isopropyl myristate must be present.
  5. Citric acid and hexylene glycol must be present.
  6. The treatment must occur before bedtime.
  7. The formulation must show the specified comparative efficacy and safety profile.
  8. The formulation must have greater storage stability than an aqueous formulation or buffer-based formulation.

These limitations create potential design-around routes. A rival could evaluate different rheology modifiers, replace isopropyl myristate, use a non-ethanol solvent system, develop an aqueous or emulsion formulation, alter the stereochemical composition, or pursue a formulation that does not make the claimed comparative efficacy and safety assertions.

What do dependent claims 2 through 14 add?

The dependent claims narrow the independent claim through excipient, concentration, packaging, stereochemistry, and dosing limitations.

Claims Additional limitation Commercial significance
2 Requires at least one additional carrier or excipient Broadens the practical formulation description but narrows claim 1
3 Defines eight listed stereochemical or stereoisomeric forms Covers specified compound configurations
4 Active concentration of about 1% to 20% Excludes the upper part of claim 1
5 Active concentration of about 2% to 10% A narrower concentration fallback
6 Multidose container delivering about 0.5 to 1.0 mL Protects metered multidose presentation
7 Single- or unit-dose container delivering about 0.5 to 1.0 mL Protects unit-dose presentation
8 Specifically requires the (2R,3'R) compound Closely tracks the commercial active ingredient
9 Claims the (2R,3'R) compound at 1% to 20% Combination of stereochemistry and concentration
10 Claims the (2R,3'R) compound at 2% to 10% Narrowest concentration-specific active claim
11 Adds multidose packaging to the (2R,3'R) compound Product-presentation claim
12 Adds unit-dose packaging to the (2R,3'R) compound Alternative presentation claim
13 Requires Dimethiconol Blend 20 Formulation-specific fallback
14 Requires an applied dose of about 0.5 to 2.0 mL Use and dose-volume limitation

Sofdra contains 12.45% sofpironium bromide, based on the FDA-approved product labeling. [2] That concentration falls within claims 1 and 4 but outside the narrower 2% to 10% range in claim 5. It therefore remains relevant to claims 1, 4, and the stereochemistry-specific claims if the other formulation and method limitations are met.

What formulation elements are most important for infringement?

The highest-value formulation limitations are likely the combination of:

  • anhydrous ethanol;
  • hydroxypropyl cellulose;
  • isopropyl myristate;
  • citric acid;
  • hexylene glycol; and
  • the defined sofpironium stereoisomer.

A generic or follow-on product containing the same active ingredient at a similar concentration would not automatically infringe. The formulation must also be compared against the complete claim language.

The stability limitation may require technical evidence. A patentee would likely need comparative stability data showing that the claimed anhydrous formulation has greater storage stability than a formulation using water or an aqueous buffer. The comparative safety and efficacy limitations may also require clinical, pharmacodynamic, or label-supported evidence.

The claim does not merely require reduced sweating. It requires at least a 25% reduction for at least six hours and a reduction substantially equivalent to topical glycopyrrolate at the same concentration, together with an improved safety profile. Those limitations may create proof issues in litigation, particularly if the accused product has different dosing instructions or does not use glycopyrrolate as a comparator.

When does U.S. Patent 10,952,990 expire?

The patent issued on March 23, 2021. [3] A precise expiration date depends on the patent family’s earliest effective nonprovisional filing date, any terminal disclaimer, patent-term adjustment, and patent-term extension.

The claim text alone does not establish the expiration date. The controlling sources are the USPTO patent-term records, the patent’s continuity data, and any FDA Orange Book listing. A patent-number search should not be used as a substitute for the USPTO term calculation.

The patent’s enforceability also depends on maintenance-fee payment, post-grant proceedings, terminal disclaimers, and any litigation judgment affecting particular claims.

What is the FDA and Orange Book status of the Sofdra patent estate?

FDA approved Sofdra for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients aged nine years and older. [1] The product is a prescription topical gel containing sofpironium bromide.

The FDA Orange Book identifies patents submitted by an approved drug sponsor when those patents meet listing requirements for the drug substance, drug product, or approved method of use. [4] A listed method-of-use or formulation patent can create a Paragraph IV challenge pathway for an abbreviated new drug application, subject to the statutory notice and litigation provisions.

Patent 10,952,990 should be evaluated against the current Orange Book entry for Sofdra, rather than assumed to be listed solely because it covers the product’s formulation. Listing status can change through FDA updates, patent delisting, expiration, or sponsor submissions.

Are there Paragraph IV challenges or generic litigation?

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. The supplied claim set does not establish that an ANDA applicant has filed a Paragraph IV certification, that Brickell has received a Paragraph IV notice, or that litigation has been initiated under the Hatch-Waxman statute.

The principal litigation issues would likely include:

  1. Written description and enablement for the broad stereochemical and concentration ranges.
  2. Indefiniteness of “substantially equivalent” efficacy and “improved safety profile.”
  3. Obviousness over topical glycopyrrolate, earlier sofpironium formulations, and conventional anhydrous gel systems.
  4. Infringement of the excipient combination.
  5. Proof of the comparative storage-stability limitation.
  6. Whether the accused product’s labeling induces the claimed before-bedtime use.

The comparative language may be valuable commercially but vulnerable legally if the specification does not provide sufficient objective testing methods or representative data across the full scope of claim 1.

How does this patent compare with glycopyrronium bromide patents?

Sofdra and Qbrexza occupy adjacent but distinct anticholinergic markets.

Issue Sofdra Qbrexza
Active ingredient Sofpironium bromide Glycopyrronium tosylate
Product type Topical gel Topical cloth
Main indication Primary axillary hyperhidrosis Primary axillary hyperhidrosis
Sponsor history Brickell Biotech Dermira, later acquired by Eli Lilly
FDA approval 2024 2018
Patent focus Sofpironium formulation and use Glycopyrronium drug product, cloth delivery, and use
Generic pathway Potential ANDA against listed Sofdra patents Potential ANDA or other follow-on pathway against Qbrexza patents

Qbrexza’s active ingredient is glycopyrronium tosylate, not sofpironium bromide. A generic Qbrexza product would not practice the sofpironium compound limitation in Patent 10,952,990. Conversely, a sofpironium competitor could avoid Qbrexza patents but still face the Sofdra patent estate.

What biosimilar risk exists?

Biosimilar risk is negligible for this product. Sofdra is a small-molecule drug, not a biologic. The relevant regulatory pathway is an ANDA or, depending on the product and differences, a 505(b)(2) application. The principal barriers are formulation patents, method-of-use patents, FDA exclusivity, bioequivalence or comparative clinical requirements, and manufacturing know-how.

A 505(b)(2) applicant could pursue a different formulation or dosing regimen, but it would still need to address listed patents and any applicable exclusivity.

What licensing deals and companies control the asset?

Sofpironium was originally associated with Dermira. Brickell obtained rights to develop and commercialize sofpironium bromide and later advanced the product through FDA review. Eli Lilly acquired Dermira in 2020, making the historical Dermira transaction relevant to chain-of-title and retained-rights analysis. [5]

The practical IP-control questions are:

  • whether Brickell owns or exclusively licenses the patent family;
  • whether Dermira or Eli Lilly retained rights;
  • whether the license covers the United States, global territories, or selected fields of use;
  • whether sublicensing rights exist;
  • whether milestone, royalty, or reversion provisions affect commercialization; and
  • whether later continuation patents are controlled by the same party.

What generic launch scenarios exist?

The most plausible launch scenarios are:

At-risk launch

An ANDA applicant launches before final patent resolution after certifying that the patent is invalid, unenforceable, or not infringed. This creates exposure to injunction, damages, and a 30-month stay if statutory conditions are met.

Launch after patent expiration

The applicant waits until the relevant listed patent or patents expire. This minimizes litigation risk but delays market entry.

Design-around launch

A competitor develops a formulation that omits at least one required excipient or uses a different vehicle, rheology modifier, stereochemical composition, dose volume, or administration schedule.

505(b)(2) launch

A company pursues a modified topical product with different concentration, delivery system, indication, or dosing regimen. This pathway may create a separate patent-certification and labeling strategy.

How strong is the patent estate?

Patent 10,952,990 has meaningful commercial scope because claim 1 combines the active ingredient with a formulation architecture that appears aligned with the approved product. Claims 8 through 12 provide narrower protection centered on the (2R,3'R) stereoisomer and dose presentation.

Its principal strengths are:

  • close alignment with a commercial formulation;
  • coverage of multiple concentration ranges;
  • stereochemistry-specific fallback claims;
  • packaging and dose-volume claims;
  • method-of-use coverage tied to hyperhidrosis treatment.

Its principal vulnerabilities are:

  • broad functional comparative limitations;
  • possible indefiniteness around “substantially equivalent” and “improved safety profile”;
  • obviousness challenges based on known anticholinergics and topical gel excipients;
  • potential design-around options;
  • uncertainty over whether every formulation limitation is present in the marketed product and any future generic.

Key Takeaways

  • U.S. Patent 10,952,990 is a formulation-and-use patent centered on sofpironium bromide for hyperhidrosis.
  • Claim 1 requires an anhydrous ethanol gel with hydroxypropyl cellulose, isopropyl myristate, citric acid, and hexylene glycol.
  • The commercial 12.45% Sofdra concentration falls within the broad 1% to 25% and 1% to 20% claim ranges.
  • Claims 8 through 12 specifically target the (2R,3'R) sofpironium stereoisomer and defined packaging formats.
  • The patent does not cover every sofpironium formulation. Excipient substitution and vehicle changes may create design-around opportunities.
  • Sofdra is a small-molecule product, so biosimilar risk does not apply.
  • Generic competition would proceed through an ANDA or potentially a 505(b)(2) application.
  • Exact expiration, Orange Book listing, Paragraph IV activity, and litigation status must be determined from the current USPTO, FDA, and court records.

FAQs

Is U.S. Patent 10,952,990 a composition patent or a method patent?

It is principally a method patent. The claims require treating hyperhidrosis by administering a defined anhydrous topical gel. The formulation limitations are embedded in the method claims.

Does a 12.45% sofpironium gel fall within the patent?

The 12.45% concentration falls within the claimed 1% to 25% and 1% to 20% ranges. Infringement would still depend on the remaining formulation, stereochemical, dosing, clinical-performance, and stability limitations.

Can a competitor avoid the patent by using an aqueous sofpironium formulation?

Potentially. Claim 1 expressly requires an anhydrous topical gel and anhydrous ethanol. An aqueous formulation would not literally satisfy those limitations, although other patents or the doctrine of equivalents could remain relevant.

Does the patent cover treatment of palmar or plantar hyperhidrosis?

Claim 1 is not expressly limited to axillary hyperhidrosis. It refers to skin of an area suffering from hyperhidrosis. The FDA approval for Sofdra is narrower and concerns primary axillary hyperhidrosis, so regulatory labeling and patent scope must be analyzed separately.

Is sofpironium the same active ingredient as glycopyrronium?

No. Sofpironium bromide and glycopyrronium salts are different anticholinergic compounds. Patent 10,952,990 uses topical glycopyrrolate as a comparative reference but claims a sofpironium-related compound as the active ingredient.

References

  1. U.S. Food and Drug Administration. (2024, June 18). FDA approves new treatment for primary axillary hyperhidrosis. https://www.fda.gov
  2. U.S. Food and Drug Administration. (2024). Sofdra (sofpironium) topical gel prescribing information. https://www.accessdata.fda.gov
  3. U.S. Patent No. 10,952,990. (2021). Topical compositions and methods of use thereof. United States Patent and Trademark Office.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
  5. Eli Lilly and Company. (2020). Lilly completes acquisition of Dermira. https://investor.lilly.com

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,952,990

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Botanix Sb SOFDRA sofpironium bromide GEL, METERED;TOPICAL 217347-001 Jun 18, 2024 RX Yes Yes 10,952,990 ⤷  Start Trial TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,952,990

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015229243 ⤷  Start Trial
Australia 2016297601 ⤷  Start Trial
Australia 2017298469 ⤷  Start Trial
Australia 2019257421 ⤷  Start Trial
Australia 2023202689 ⤷  Start Trial
Australia 2024227714 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.